Charles Schwab Investment Management Inc. Grows Holdings in Pediatrix Medical Group, Inc. $MD

Charles Schwab Investment Management Inc. grew its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 7.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,552,585 shares of the company’s stock after acquiring an additional 105,345 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Pediatrix Medical Group were worth $33,210,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in MD. Victory Capital Management Inc. raised its stake in shares of Pediatrix Medical Group by 30.7% in the 3rd quarter. Victory Capital Management Inc. now owns 4,126,207 shares of the company’s stock valued at $69,114,000 after acquiring an additional 968,553 shares during the period. American Century Companies Inc. grew its holdings in shares of Pediatrix Medical Group by 38.9% in the third quarter. American Century Companies Inc. now owns 2,682,976 shares of the company’s stock valued at $44,940,000 after purchasing an additional 751,109 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Pediatrix Medical Group in the fourth quarter valued at approximately $13,613,000. Ameriprise Financial Inc. grew its holdings in shares of Pediatrix Medical Group by 175.4% in the second quarter. Ameriprise Financial Inc. now owns 744,473 shares of the company’s stock valued at $10,683,000 after purchasing an additional 474,186 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Pediatrix Medical Group by 669.4% in the second quarter. BNP Paribas Financial Markets now owns 476,098 shares of the company’s stock valued at $6,832,000 after purchasing an additional 414,216 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Shirley A. Weis sold 36,028 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.80% of the company’s stock.

Pediatrix Medical Group Trading Down 4.5%

Shares of Pediatrix Medical Group stock opened at $22.43 on Friday. The company has a fifty day simple moving average of $21.54 and a 200-day simple moving average of $21.56. Pediatrix Medical Group, Inc. has a 12-month low of $11.84 and a 12-month high of $24.99. The company has a current ratio of 1.33, a quick ratio of 1.33 and a debt-to-equity ratio of 0.45. The stock has a market cap of $1.84 billion, a price-to-earnings ratio of 10.89 and a beta of 0.70.

Pediatrix Medical Group (NYSE:MD) last issued its earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The business had revenue of $476.20 million during the quarter, compared to analysts’ expectations of $465.83 million. During the same quarter in the prior year, the business posted $0.33 EPS. The company’s revenue for the quarter was up 3.9% on a year-over-year basis. On average, equities analysts forecast that Pediatrix Medical Group, Inc. will post 2.08 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on MD. Jefferies Financial Group restated a “buy” rating and issued a $27.00 price objective on shares of Pediatrix Medical Group in a report on Monday, April 20th. Zacks Research cut shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a report on Friday, February 20th. UBS Group lifted their price objective on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday. Finally, Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a report on Friday, May 8th. One research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $22.50.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.